PCSK9 Inhibition Ameliorates Experimental Autoimmune Myocarditis by Reducing TH17 Cell Differentiation Through LDLR/STAT-3/ROR-γT Pathway
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923012870?via=ihub
Proprotein convertase subtilisin kexin type 9 (PCSK9) was characterized as a protein regulating circulating cholesterol metabolism; however, recent st...
PCSK9 inhibition ameliorated the severity of EAM mice by reducing Th17 cell differentiation. PCSK9 is a promising target for treating myocarditis.
Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia Across Five Countries: Analysis From the ZERBINI Study
Source : https://link.springer.com/article/10.1007/s40119-023-00334-5
Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries. Methods This retrospective and prospective observational study enrolled patients...
These findings provide real-world evidence that evolocumab use is in accordance with its international guideline-recommended place in dyslipidemia therapy, as well as confirmation of its effectiveness and safety in a heterogeneous population. Evolocumab can address a healthcare gap in the management of dyslipidemia by increasing the...
PCSK9 Inhibitors Suppress Oxidative Stress and Inflammation in Atherosclerotic Development by Promoting Macrophage Autophagy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492065/
Objectives: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of cholesterol-lowering drugs, can reduce atherosclerosis independent of systemic lipid changes. However, the mechanism by which PCSK9 inhibition protects...
This study reveals a novel protective mechanism by which PCSK9 inhibition enhances autophagy and thereby reduces oxidative stress and inflammation in atherosclerosis.
Long-Term Safety and Effectiveness of Alirocumab and Evolocumab in Familial Hypercholesterolemia (FH) in Belgium
Source : https://pubmed.ncbi.nlm.nih.gov/37767917/
Background: In 2019, the European Atherosclerosis Society (EAS) published updated guidelines, recommending even lower blood cholesterol targets than previously. In patients with familial hypercholesterolaemia (FH), who have very elevated blood...
Anti-PCSK9 mAb are a safe and effective therapeutic option for lowering LDL-C levels in FH patients. It allowed a significant portion of our FH patients to reach their lipid targets, mainly in those with combined therapy with statin and/or ezetimibe.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
Source : https://pubmed.ncbi.nlm.nih.gov/37755635/
The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a) levels in ACS CHIPs-PCI. However, further studies are needed to confirm whether PCSK9 inhibitors can reduce the...
The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a) levels in ACS CHIPs-PCI. However, further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.